FrancophonIA/ELRC3.0 huggingface dataset:
English: In paediatric patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Abseamed by the intravenous route is preferable.
Latvian: Pediatriskiem pacientiem ar hronisku nieru mazspēju, kuriem pastāvīgi ir ievietots intravenozais katetrs (hemodialīzes pacientiem), vēlams Abseamed ievadīt intravenozi.
English: What Abseamed contains
Latvian: Ko Abseamed satur
English: Talk to your doctor, pharmacist or nurse before using Abseamed.
Latvian: Pirms Abseamed lietošanas konsultējieties ar ārstu, farmaceitu vai medmāsu.
English: - All contraindications associated with autologous blood predonation programmes should be respected in patients being supplemented with Abseamed.
Latvian: - Pacientiem, kuri papildus saņem Abseamed, ir jāņem vērā visas kontrindikācijas, kas saistītas ar autologās asins transfūzijas programmām.
English: INFORMATION IN BRAILLE Abseamed 9,000 IU/0.9 mL
Latvian: Abseamed 9 000 SV/0,9 ml
English: Abseamed is one of a group of products that stimulate the production of red blood cells like the human protein erythropoietin does.
Latvian: Īpaša piesardzība, lietojot citas zāles, kas stimulē sarkano asins šūnu produkciju Abseamed pieder zāļu grupai, kas stimulē sarkano asins šūnu produkciju, līdzīgi kā cilvēka proteīns eritropoetīns.
English: In patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Abseamed by the intravenous route is preferable.
Latvian: Pacientiem ar hronisku nieru mazspēju, kuriem pastāvīgi ir ievietots intravenozais katetrs (hemodialīzes pacientiem), vēlams Abseamed ievadīt intravenozi.
English: Patients should be monitored closely to ensure that the lowest approved dose of Abseamed is used to provide adequate control of anaemia and of the symptoms of anaemia.
Latvian: Pacienti uzmanīgi jānovēro, lai pārliecinātos, ka anēmijas un anēmijas simptomu adekvātai kontrolei tiek ievadīta zemākā apstiprinātā Abseamed deva.
English: Once a syringe has been removed from the refrigerator and has reached room temperature (up to 25°C) it must either be used within 3 days or disposed of.
Latvian: 25°C), tā ir jāizlieto 3 dienu laikā vai jāiznīcina.
English: Abseamed should be administered to patients with symptomatic anaemia (e.g. haemoglobin concentration ≤ 10 g/dL (6.2 mmol/L)).
Latvian: Abseamed jāievada pacientiem ar anēmiju (piemēram, hemoglobīna koncentrācija ≤ 10 g/dl
English: INFORMATION IN BRAILLE Abseamed 7,000 IU/0.7 mL
Latvian: Abseamed 7 000 SV/0,7 ml
English: INFORMATION IN BRAILLE Abseamed 6,000 IU/0.6 mL
Latvian: Abseamed 6 000 SV/0,6 ml
English: The recommended dose is Abseamed 600 IU/kg, administered subcutaneously weekly for three weeks (days -21, -14 and -7) prior to surgery and on the day of surgery (day 0).
Latvian: Tādu pieaugušo pacientu ārstēšana, kuriem ieplānota īpaša plaša ortopēdiska operācija Ieteicamā Abseamed deva ir 600 SV/kg subkutāni katru nedēļu trīs nedēļas (21, 14 un 7 dienas) pirms operācijas un operācijas dienā (0. diena).
English: 1 pre-filled syringe of 0.75 mL 6 pre-filled syringes of 0.75 mL 1 pre-filled syringe of 0.75 mL with a needle safety guard 4 pre-filled syringes of 0.75 mL with a needle safety guard 6 pre-filled syringes of 0.75 mL with a needle safety guard
Latvian: 1 0,75 ml pilnšļirce 6 0,75 ml pilnšļirces 1 0,75 ml pilnšļirce ar adatas aizsargu 4 0,75 ml pilnšļirces ar adatas aizsargu
English: If the haemoglobin is rising by more than 2 g/dL (1.25 mmol/L) per month, or if the sustained haemoglobin exceeds 12 g/dL (7.5 mmol/L) reduce the Abseamed dose by 25%.
Latvian: Ja hemoglobīna līmeņa pieaugums mēneša laikā pārsniedz 2 g/dl (1,25 mmol/l) vai ja hemoglobīna līmenis pastāvīgi ir augstāks par 12 g/dl (7,5 mmol/l), Abseamed deva ir jāsamazina par 25%.
English: Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Each syringe contains 0.8 mL of solution for injection.
Latvian: Abseamed 8 000 SV/0,8 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 0,8 ml šķīduma.
English: Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Each syringe contains 0.9 mL of solution for injection.
Latvian: Abseamed 9 000 SV/0,9 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 0,9 ml šķīduma.
English: Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Each syringe contains 0.75 mL of solution for injection.
Latvian: Abseamed 30 000 SV/0,75 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 0,75 ml šķīduma.
English: Side effects from an overdose of Abseamed are unlikely.
Latvian: Maz ticams, ka pārāk lielas Abseamed devas injicēšana radīs blakusparādības.
English: INFORMATION IN BRAILLE Abseamed 5,000 IU/0.5 mL
Latvian: Abseamed 5 000 SV/0,5 ml
English: Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 8 000 SV/0,8 ml šķīdums injekcijām pilnšļircē
English: INFORMATION IN BRAILLE Abseamed 40,000 IU/1 mL
Latvian: Abseamed 40 000 SV/1 ml
English: INFORMATION IN BRAILLE Abseamed 4,000 IU/0.4 mL
Latvian: Abseamed 4 000 SV/0,4 ml
English: Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Each syringe contains 0.7 mL of solution for injection.
Latvian: Abseamed 7 000 SV/0,7 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 0,7 ml šķīduma.
English: INFORMATION IN BRAILLE Abseamed 20,000 IU/0.5 mL
Latvian: Abseamed 20 000 SV/0,5 ml
English: It is important to tell your doctor if any of the following apply to you.
Latvian: Ja kāds no tālāk minētajiem faktiem attiecas uz Jums, ir svarīgi pastāstīt par to savam ārstam.
English: INFORMATION IN BRAILLE Abseamed 2,000 IU/1 mL
Latvian: Abseamed 2 000 SV/1 ml
English: Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 9 000 SV/0,9 ml šķīdums injekcijām pilnšļircē
English: INFORMATION IN BRAILLE Abseamed 3,000 IU/0.3 mL
Latvian: Abseamed 3 000 SV/0,3 ml
English: Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Each syringe contains 0.4 mL of solution for injection.
Latvian: Abseamed 4 000 SV/0,4 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 0,4 ml šķīduma.
English: Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Each syringe contains 0.6 mL of solution for injection.
Latvian: Abseamed 6 000 SV/0,6 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 0,6 ml šķīduma.
English: Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 6 000 SV/0,6 ml šķīdums injekcijām pilnšļircē
English: INFORMATION IN BRAILLE Abseamed 10,000 IU/1 mL
Latvian: Abseamed 10 000 SV/1 ml
English: Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa
Latvian: Abseamed 30 000 SV/0,75 ml šķīdums injekcijām pilnšļircē
English: Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 7 000 SV/0,7 ml šķīdums injekcijām pilnšļircē
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 30,000 IU/0.75 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 30 000 SV/0,75 ml šķīdums injekcijām pilnšļircē
English: Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 4 000 SV/0,4 ml šķīdums injekcijām pilnšļircē
English: INFORMATION IN BRAILLE Abseamed 1,000 IU/0.5 mL
Latvian: Abseamed 1 000 SV/0,5 ml
English: If the patient has developed a severe cutaneous skin reaction such as SJS or TEN due to the use of Abseamed, treatment with Abseamed must not be restarted in this patient at any time.
Latvian: Ja pacientam Abseamed lietošanas dēļ ir radusies smaga ādas reakcija, piemēram, SJS vai TEN,
English: Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Each syringe contains 0.3 mL of solution for injection.
Latvian: Abseamed 3 000 SV/0,3 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 0,3 ml šķīduma.
English: Your doctor will monitor your blood pressure regularly while you are using Abseamed.
Latvian: Abseamed terapijas laikā ārsts regulāri kontrolēs Jūsu asinsspiedienu.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 7,000 IU/0.7 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 7 000 SV/0,7 ml šķīdums injekcijām pilnšļircē
English: Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 1 000 SV/0,5 ml šķīdums injekcijām pilnšļircē
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 9,000 IU/0.9 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 9 000 SV/0,9 ml šķīdums injekcijām pilnšļircē
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 40,000 IU/1 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 40 000 SV/1 ml šķīdums injekcijām pilnšļircē
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 8,000 IU/0.8 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 8 000 SV/0,8 ml šķīdums injekcijām pilnšļircē
English: Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 20 000 SV/0,5 ml šķīdums injekcijām pilnšļircē
English: 1 pre-filled syringe of 0.8 mL 6 pre-filled syringes of 0.8 mL 1 pre-filled syringe of 0.8 mL with a needle safety guard 6 pre-filled syringes of 0.8 mL with a needle safety guard
Latvian: 1 0,8 ml pilnšļirce ar adatas aizsargu 6 0,8 ml pilnšļirces ar adatas aizsargu
English: Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Latvian: Abseamed 5 000 SV/0,5 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 0,5 ml šķīduma.
English: Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Latvian: Abseamed 20 000 SV/0,5 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 0,5 ml šķīduma.
English: Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 40 000 SV/1 ml šķīdums injekcijām pilnšļircē
English: Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 3 000 SV/0,3 ml šķīdums injekcijām pilnšļircē
English: Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Latvian: Abseamed 1 000 SV/0,5 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 0,5 ml šķīduma.
English: Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 5 000 SV/0,5 ml šķīdums injekcijām pilnšļircē
English: Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Latvian: Abseamed 40 000 SV/1 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 1 ml šķīduma.
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Latvian: Abseamed 2 000 SV/1 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 1 ml šķīduma.
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 2 000 SV/1 ml šķīdums injekcijām pilnšļircē
English: 1 pre-filled syringe of 0.7 mL 6 pre-filled syringes of 0.7 mL 1 pre-filled syringe of 0.7 mL with a needle safety guard 6 pre-filled syringes of 0.7 mL with a needle safety guard
Latvian: 1 0,7 ml pilnšļirce ar adatas aizsargu 6 0,7 ml pilnšļirces ar adatas aizsargu
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 1,000 IU/0.5 mL injection
Latvian: REĢISTRĀCIJAS APLIECĪBAS NUMURS(-I) Abseamed 1 000 SV/0,5 ml šķīdums injekcijām pilnšļircē
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 3,000 IU/0.3 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 3 000 SV/0,3 ml šķīdums injekcijām pilnšļircē
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 6,000 IU/0.6 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 6 000 SV/0,6 ml šķīdums injekcijām pilnšļircē
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 4,000 IU/0.4 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 4 000 SV/0,4 ml šķīdums injekcijām pilnšļircē
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 10,000 IU/1 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 10 000 SV/1 ml šķīdums injekcijām pilnšļircē
English: A pre-filled syringe of 1 mL contains 2,000 international units (IU) corresponding to 16.8 micrograms epoetin alfa.
Latvian: 1 ml pilnšļirce satur 2 000 starptautiskās vienības (SV), kas atbilst 16,8 mikrogramiem alfa epoetīna.*
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Latvian: Abseamed 10 000 SV/1 ml šķīdums injekcijām pilnšļircē Katrā pilnšļircē ir 1 ml šķīduma.
English: What is in this leaflet What Abseamed is and what it is used for What you need to know before you use Abseamed How to use Abseamed Possible side effects How to store Abseamed Contents of the pack and other information What Abseamed is and what it is used for Abseamed contains the active substance epoetin alfa, a protein that stimulates the bone marrow to produce more red blood cells which carry haemoglobin (a substance that transports oxygen).
Latvian: Abseamed satur aktīvo vielu alfa epoetīnu, proteīnu, kas stimulē kaulu smadzenes ražot vairāk sarkanās asins šūnas, kas transportē hemoglobīnu (viela, kas transportē skābekli).
English: Where intravenous access is not readily available Abseamed may be administered subcutaneously.
Latvian: Ja pacientam nav ievietots intravenozais katetrs, Abseamed var ievadīt subkutāni.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 2,000 IU/1 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 2 000 SV/1 ml šķīdums injekcijām pilnšļircē
English: 1 pre-filled syringe of 1 mL contains 2,000 international units (IU) corresponding to 16.8 micrograms epoetin alfa.
Latvian: NOSAUKUMS(-I) UN DAUDZUMS(-I) Viena 1 ml pilnšļirce satur 2 000 starptautiskās vienības (SV), kas atbilst 16,8 mikrogramiem alfa epoetīna.
English: Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL
Latvian: Katrs ml šķīduma satur 40 000 SV alfa epoetīna* (epoetin alfa), kas atbilst 336,0 mikrogramiem/ml.
English: What Abseamed looks like and contents of the pack
Latvian: Abseamed ārējais izskats un iepakojums
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe
Latvian: Abseamed 10 000 SV/1 ml šķīdums injekcijām pilnšļircē
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 20,000 IU/0.5 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 20 000 SV/0,5 ml šķīdums injekcijām pilnšļircē
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Latvian: Katrs ml šķīduma satur 10 000 SV alfa epoetīna* (epoetin alfa), kas atbilst 84,0 mikrogramiem/ml.
English: Serious skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with epoetin treatment.
Latvian: Īpaša piesardzība, lietojot Abseamed, nepieciešama šādos gadījumos Saistībā ar epoetīna lietošanu ziņots par nopietnām ādas reakcijām, ieskaitot Stīvensa-Džonsona sindromu (SJS- Stevens-Johnson syndrome) un toksisku epidermas nekrolīzi (TEN).
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 2,000 IU of epoetin alfa* corresponding to 16.8 micrograms per mL
Latvian: Katrs ml šķīduma satur 2 000 SV alfa epoetīna* (epoetin alfa), kas atbilst 16,8 mikrogramiem/ml
English: - The other ingredients are: sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, sodium chloride, glycine, polysorbate 80, hydrochloric acid (for pH-adjustment), sodium hydroxide (for pH-adjustment), and water for injections.
Latvian: - Citas sastāvdaļas ir: nātrija dihidrogēnfosfāta dihidrāts, nātrija hidrogēnfosfāta dihidrāts,
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 5,000 IU/0.5 mL injection
Latvian: ZĀĻU NOSAUKUMS Abseamed 5 000 SV/0,5 ml šķīdums injekcijām pilnšļircē
English: 1 pre-filled syringe of 0.3 mL 6 pre-filled syringes of 0.3 mL 1 pre-filled syringe of 0.3 mL with a needle safety guard 6 pre-filled syringes of 0.3 mL with a needle safety guard
Latvian: 1 0,3 ml pilnšļirce 6 0,3 ml pilnšļirces 1 0,3 ml pilnšļirce ar adatas aizsargu
English: Treatment of adult patients scheduled for major elective orthopaedic surgery
Latvian: Tādu pieaugušo pacientu ārstēšana, kuriem ieplānota plaša ortopēdiska operācija Abseamed jāievada subkutānas injekcijas veidā.
English: Abseamed should be administered as a subcutaneous injection.
Latvian: Ķīmijterapijas izraisītu anēmiju ārstēšana pieaugušiem pacientiem Abseamed jāievada subkutānas injekcijas veidā.
English: Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe EU/1/07/412/023
Latvian: Abseamed 30 000 SV/0,75 ml injekcijām Epoetin alfa i.v./s.c.
English: The patients were between 22 months and 72 years old.
Latvian: Šie pacienti bija vecumā no 22 mēnešiem līdz 72 gadiem.
English: A specialized antidote is not available.
Latvian: Īpašs antidots nav pieejams.
English: The duration of the treatment is determined by the doctor and may vary for each patient.
Latvian: Ārstēšanas ilgumu nosaka ārsts, un tas katram pacientam var atšķirties.
English: Lung damage may occur years after treatment.
Latvian: Plaušu bojājumi var rasties vairākus gadus pēc ārstēšanas.
English: 1081 CN Amsterdam The Netherlands
Latvian: 1081 CN Amsterdam
English: This medicine will be stored by your doctor or health care professional.
Latvian: Šīs zāles uzglabās Jūsu ārsts vai veselības aprūpes speciālists.
English: Tell you doctor or nurse if you have any concern about the amount of medicine that you received.
Latvian: Pasakiet ārstam vai medmāsai, ja Jums radušās bažas par saņemto zāļu daudzumu.
English: Store and transport refrigerated (2°C - 8°C).
Latvian: Uzglabāt un transportēt atdzesētu (2-8 °C).
English: Pulmonary toxicity has been observed in up to 30% of patients.
Latvian: Plaušu toksicitāte ir novērota līdz 30 % pacientu.
English: As a doctor or nurse will be giving you this medicine, it is unlikely that you will receive an incorrect dose.
Latvian: Tā kā šīs zāles Jums ievadīs ārsts vai medmāsa, ir maz ticams, ka Jūs varētu saņemt nepareizu devu.
English: Carmustine Obvius should not be used during pregnancy because it may harm your unborn baby.
Latvian: Carmustine Obvius nedrīkst lietot grūtniecības laikā, jo tās var kaitēt vēl nedzimušajam bērnam.
English: Two of these 8 fatalities occurred within the first 3 years of treatment and 6 of them occurred 8-13 years after treatment.
Latvian: Divos no šiem 8 gadījumiem pacientiem nāve iestājās pirmo 3 gadu laikā pēc ārstēšanas, bet 6 gadījumos pacienti nomira 8-13 gadus pēc ārstēšanas.
English: If such symptoms occur, you should contact your doctor immediately (see section
Latvian: Ja Jums rodas šādi simptomi, nekavējoties sazinieties ar ārstu (skatīt 4. punktu).
English: Your doctor will talk to you about the possibility of lung damage and allergic reactions and their symptoms.
Latvian: Ārsts Jūs informēs par plaušu bojājumu un alerģisku reakciju iespējamību un to simptomiem.
English: The median age of patients who died on treatment was 2.5 years (1-12 years), the median age of long-term survivors on treatment was 10 years (5-16 years).
Latvian: Ārstēto pacientu vecuma mediāna nāves brīdī bija 2,5 gadi (1-12 gadi), un ilgstoši izdzīvojušo ārstēto pacientu vecuma mediāna nāves brīdī bija 10 gadi (5-16 gadi).
English: Emetogenic potential.
Latvian: Emetogēnais potenciāls
English: The half-life α is 1-4 minutes and the half-life β is 18-69 minutes.
Latvian: Eliminācijas pusperiods α ir 1-4 minūtes, bet eliminācijas pusperiods β ir 18-69 minūtes.
English: This medicine may cause severe (possibly fatal) lung damage.
Latvian: Šīs zāles var izraisīt smagus (reizēm arī nāvējošus) plaušu bojājumus.
English: Other medicines and Carmustine Obvius
Latvian: Citas zāles un Carmustine Obvius
English: Therefore this medicine should not normally be administered to pregnant women.
Latvian: Tāpēc šīs zāles parasti nedrīkst lietot grūtniecēm.
English: The 30 ml stock solution needs to be mixed thoroughly.
Latvian: Iegūtais 30 ml izejas šķīdums ir rūpīgi jāsajauc.
English: Compatibility/Incompatibility with containers
Latvian: Saderība/nesaderība ar tvertnēm
English: Reconstitution and further dilutions should be carried out under aseptic conditions.
Latvian: Zāļu sagatavošana un atšķaidīšana jāveic aseptiskos apstākļos.
English: Doses will be adjusted according to how you respond to the treatment.
Latvian: Deva tiks pielāgota atbilstoši Jūsu atbildes reakcijai uz ārstēšanu.
English: What Carmustine Obvius is and what it is used for
Latvian: Kas ir Carmustine Obvius un kādam nolūkam tās lieto
English: Safe use in pregnancy has not been established and therefore the benefit must be carefully weighed against the risk of toxicity.
Latvian: Lietošanas drošums grūtniecības laikā nav noteikts, tāpēc ir rūpīgi jāizvērtē ieguvums un toksicitātes risks.
English: The amount of alcohol in this medicine may alter the effects of other medicines.
Latvian: Alkohola daudzums šajās zālēs var mainīt citu zāļu iedarbību.
English: Children and adolescents
Latvian: Bērni un pusaudži.
English: In patients having received carmustine in childhood or adolescence, cases of extremely delayedonset pulmonary fibrosis (up to 17 years after treatment) have been described.
Latvian: Pacientiem, kuri karmustīnu saņēmuši bērnībā vai pusaudžu gados, ir aprakstīti ļoti aizkavēti plaušu fibrozes gadījumi (līdz 17 gadiem pēc ārstēšanas).
English: Approximately 60-70% of a total dose is excreted in the urine in 96 hours and about 10% as respiratory CO2.
Latvian: Apmēram 60-70 % no kopējās devas izdalās urīnā 96 stundu laikā, bet apmēram 10 % izdalās respiratori kā CO2. Atlikušā daudzuma eliminācija vēl nav noteikta.
English: Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed may not reflect the rates observed in clinical practice.
Latvian: Tā kā klīniskie pētījumi ir veikti ļoti specifiskos apstākļos, novērotais nevēlamo blakusparādību biežums var neatbilst biežumam, kas novērojams klīniskajā praksē.
English: Posology and laboratory investigations
Latvian: Devas un laboratoriskie izmeklējumi
English: Levels of radioactivity in the cerebrospinal fluid are at least 50% higher than those measured concurrently in plasma.
Latvian: Radioaktivitātes līmenis cerebrospinālajā šķidrumā parasti ir vismaz par 50 % augstāks nekā vienlaikus mērītais līmenis plazmā.
English: Carmustine Obvius with alcohol
Latvian: Carmustine Obvius un alkohols
English: Such products are not accepted for use due to the risk of temperature excursions to more than 30°C.This medicinal product should not be used any further.
Latvian: Šādu zāļu lietošana nav pieļaujama, jo pastāv risks, ka tās bijušas pakļautas temperatūrai, kas pārsniedz 30 °C. Šādas zāles vairs nedrīkst lietot.
English: Direct administration of carmustine into the carotid artery is regarded as experimental and has been associated with ocular toxicity.
Latvian: Karmustīna tieša ievadīšana miega artērijā tiek uzskatīta par eksperimentālu un ir saistīta ar okulāro toksicitāti.
English: Dosage is based on your medical condition, body size and response to treatment.
Latvian: Deva ir atkarīga no Jūsu veselības stāvokļa, ķermeņa virsmas laukuma un reakcijas uz ārstēšanu.
English: Carmustine Obvius will always be given to you by a healthcare professional with experience in the use of anticancer medicines.
Latvian: Carmustine Obvius vienmēr ievadīs veselības aprūpes speciālists ar pieredzi pretvēža zāļu lietošanā.
English: Hypersensitivity to the active substance, to other nitrosoureas or to any of the excipients listed in section 6.1.
Latvian: Paaugstināta jutība pret aktīvo vielu, citiem nitrozourīnvielas atvasinājumiem vai jebkuru no 6.1. apakšpunktā uzskaitītajām palīgvielām.